SEC charges Bausch Health subsidiary Salix Pharmaceuticals with misleading investors 

  • Salix Pharmaceuticals, a unit of Bausch Health Companies Inc, has moved to settle charges brought by the U.S. Securities and Exchange Commission
  • The company misled investors about the company's prospects, the SEC said on Friday.
The U.S. Securities and Exchange Commission in Washington, D.C.
Adam Jeffery | CNBC
The U.S. Securities and Exchange Commission in Washington, D.C.

Salix Pharmaceuticals, a unit of Bausch Health Companies, has moved to settle charges brought by the U.S. Securities and Exchange Commission that it misled investors about the company's prospects, the SEC said on Friday.

As part of the proposed settlement, which must be approved by a U.S. district court, Salix agreed to be enjoined from future violations of antifraud and corporate reporting provisions of federal securities laws, the agency said.